BIOEOTCPharmaceutical PreparationsFiscal year ends December 31
Bio Essence Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.42+0.03 (+7.72%)
Close on Oct 19, 2026
- Market cap
- $21.38M
- P/E (TTM)
- 10.5
- Dividend yield
- –
Bio Essence Corp revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q3 23 | Q2 23 | Q1 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from OEM services | $794.71K | $500.54K | – | – | $259.12K | $20.97K | – | – | – | – | – | – | 100.0% | +206.7% |
| Sales of goods | – | – | – | – | – | – | $0 | $37.42K | $41.70K | $116.15K | $141.91K | $149.76K | – | – |
| Manufacture service revenue | – | – | – | $136.80K | $259.12K | $20.97K | $146.64K | $94.41K | – | $39.55K | $117.67K | $191.57K | – | – |
| Shipping and delivery Income | – | – | $0 | $0 | $0 | $1.22K | $912 | $2.86K | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Bio Essence's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.